natgillin/translations-raw huggingface dataset:
I interaktionsundersøgelser havde laropiprant ingen klinisk signifikant indvirkning på farmakokinetikken af følgende lægemidler: Simvastatin, warfarin, perorale kontraceptiva, rosiglitazon og digoxin.
In interaction studies, laropiprant did not have clinically significant effects on the pharmacokinetics of the following medicinal products: simvastatin, warfarin, oral contraceptives, rosiglitazone and digoxin.
Medicinen fås som en tablet med modificeret udløsning.
The medicine comes as a modified-release tablet.
• Udslæt med flade, røde pletter
• rash with flat, red spots
Dyreforsøg har vist udskillelse af laropiprant i mælken.
Animal studies have shown excretion of laropiprant in milk.
Pelzont indeholder nicotinsyre, som i terapeutiske doser er et lipidmodificerende stof, og laropiprant, der er en potent, selektiv prostaglandin D2-antagonist (PGD2) receptorsubtype 1 (DP1).
Pelzont contains nicotinic acid, which at therapeutic doses is a lipid-modifying agent, and laropiprant, a potent, selective antagonist of the prostaglandin D2 (PGD2) receptor subtype 1 (DP1).
Primær betyder, at årsagen til hyperkolesterolæmien ikke er kendt.
Primary means that the hypercholesterolaemia does not have any identifiable cause.
Totalt kolesterol består hovedsageligt af "dårligt" (LDL) og "godt" (HDL) kolesterol.
Your total cholesterol is made up mainly of ‘bad' (LDL) and ‘good' (HDL) cholesterol.
Reduktionen af flushing-symptomer (vurderet ved hjælp af patientspørgeskemaer) blev korreleret med en reduktion i nicotinsyreinduceret vasodilatation (vurderet ved hjælp af målinger af blodgennemstrømningen i huden).
The reduction in flushing symptoms (assessed by patient questionnaires) was correlated with a reduction in nicotinic acid-induced vasodilatation (assessed by measurements of skin blood flow).
Indehaveren af markedsføringstilladelsen skal udføre de lægemiddelovervågningsaktiviteter, som er beskrevet i lægemiddelovervågningsplanen (ifølge aftalen i RMP modul 1.8.2 i markedsføringstilladelsen), og enhver efterfølgende opdatering af RMP, som er godkendt af Udvalget for Lægemidler til Mennesker (CHMP).
The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP).
For at bevare egenskaberne ved den modificerede udløsning, må tabletterne ikke deles, brydes, knuses eller tygges, før de sluges.
To preserve the modified-release properties, the tablets must not be split, broken, crushed, or chewed before swallowing.
• Medicin til at sænke kolesterol kaldet "statiner".
• medicines used to lower cholesterol called ‘statins'.
Midazolam: Flergangsdosering med laropiprant 40 mg påvirkede ikke midazolams farmakokinetik, der er et sensitivt CYP3A4-substrat.
Midazolam: Multiple doses of laropiprant 40 mg did not affect the pharmacokinetics of midazolam, a sensitive CYP3A4 substrate.
Kvinder har en beskeden stigning i nicotinurinsyres og nicotinsyres plasmakoncentration sammenlignet med mænd.
Women have a modest increase in plasma concentrations of nicotinuric acid and nicotinic acid compared to men.
Men hvis De ikke har taget Pelzont i 7 dage eller mere i træk, skal De tale med lægen, før De igen begynder at tage Pelzont.
However, if you do not take Pelzont for 7 or more days in a row, talk to your doctor before restarting Pelzont.
Fortæl altid lægen eller på apoteket, hvis De bruger anden medicin eller har gjort det for nylig.
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Da l'-hydroxymidazolam er en aktiv metabolit, kan midazolams sedative virkning øges, og forsigtighed bør udvises, når laropiprant gives samtidigt med midazolam.
Because 1'-hydroxymidazolam is an active metabolite, the sedative effect of midazolam may be increased and caution should be used when laropiprant is co-administered with midazolam.
Denne effekt forventes ikke at have klinisk betydning, da laropiprant ikke øgede blødningstiden, når det blev administreret sammen med clopidogrel i hele doseringsintervallet.
This effect is unlikely to be clinically important as laropiprant did not increase bleeding time when co-administered with clopidogrel throughout the dosing interval.
Patienter med arvelig galactoseintolerans, en særlig form for arvelig lactasemangel (Lapp Lactase deficiency) eller glucose/-galactosemalabsorption bør ikke tage dette lægemiddel.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Pelzont er ikke undersøgt hos børn og unge under 18 år.
Pelzont has not been studied in children and adolescents who are under 18 years of age.
Pelzont må ikke anvendes under graviditet, med mindre det er klart nødvendigt.
Pelzont is not recommended in pregnancy unless clearly necessary.
• Slug tabletten hel.
• Swallow each tablet whole.
Hos mennesker metaboliseres nicotinamid desuden overvejende til Nmethylnicotinamid (MNA) og til N-methyl-2-pyridon-5-carboxamid (2PY).
In humans, nicotinamide is further predominantly metabolised to N-methylnicotinamide (MNA) and to N-methyl-2-pyridone-5-carboxamide (2PY).
Metaboliseringsvejen, hvor glycin konjugeres, mættes ikke gennem det klinisk relevante dosisområde på basis af den dosisproportionale stigning i plasmakoncentrationen af NUA fra 1.000-2.000 mg.
The glycine conjugation pathway is not saturated across the clinically relevant dose range, based on the dose-proportional increase in the plasma concentrations of NUA from 1,000 mg to 2,000 mg.
Da nicotinsyre og dets metabolitter udskilles via nyrerne, bør Pelzont anvendes med forsigtighed hos patienter med nyreinsufficiens.
Because nicotinic acid and its metabolites are excreted through the kidneys, Pelzont should be used with caution in patients with renal dysfunction.
Ved primær hyperkolesterolæmi er indholdet af kolesterol i blodet højt.
Primary hypercholesterolaemia is when the levels of cholesterol in the blood are high.
Laropiprant: I overensstemmelse med karakteristika for et lægemiddel, der primært elimineres via metabolisme, har moderat leversygdom signifikant indvirkning på laropiprants farmakokinetik med en stigning i AUC og Cmax på henholdsvis ca. 2,8 og 2,2 gange.
Laropiprant: Consistent with the characteristics of a medicinal product that is primarily cleared by metabolism, moderate hepatic disease has a significant impact on laropiprant pharmacokinetics, with an increase in AUC and Cmax of approximately 2.8- and 2.2-fold respectively.
Laropiprants oxidative metabolisme katalyseres primært af CYP3A4, mens mange UGT-isoformer (1A1, 1A3, 1A9 og 2B7) katalyserede acylglucuronideringerne.
The oxidative metabolism of laropiprant is catalysed primarily by CYP3A4, whereas several UGT isoforms (1A1, 1A3, 1A9 and 2B7) catalysed the acyl glucuronidation.
• når der modtages nye oplysninger, der kan have indflydelse på den gældende sikkerhedsspecifikation, lægemiddelovervågningsplan eller på risikominimeringsaktiviteter
• When new information is received that may impact on the current Safety Specification,
Laropiprant har vist sig at være effektiv til at reducere flushing-symptomer, der er induceret af nicotinsyre.
Laropiprant has been shown to be effective in reducing flushing symptoms induced by nicotinic acid.
Nicotinsyre udskilles overvejende i urinen som metabolitter.
Nicotinic acid is predominantly excreted in the urine as metabolites.
Laropiprants farmakokinetik er lineær og udviser omtrentlige dosisproportionale stigninger i AUC og Cmax og ingen tegn på tidsafhængig clearance.
The pharmacokinetics of laropiprant are linear, displaying approximately dose-proportional increases in AUC and Cmax and no evidence of time-dependent clearance.
HDL-kolesterol kaldes ofte det "gode" kolesterol, fordi det er med til at forhindre det "dårlige" kolesterol i at tilstoppe blodårerne, og fordi det beskytter mod hjertesygdom.
HDL cholesterol is often called ‘good' cholesterol because it helps keep the ‘bad' cholesterol from building up in the arteries and because it protects against heart disease.
Det antages, at HDL deltager i transporten af kolesterol fra vævene tilbage til leveren for at hæmme vaskulær inflammation, der er forbundet med aterosklerose, og for at have antioxidativ og antitrombotisk effekt.
HDL is hypothesised to participate in the transport of cholesterol from tissues back to the liver, to suppress vascular inflammation associated with atherosclerosis, and to have anti-oxidative and anti-thrombotic effects.
Nicotinsyre viste ingen mutagen effekt i in vitro-assays.
Nicotinic acid showed no mutagenic effects in the in vitro assays.
Nicotinsyreinduceret flushing er primært medieret ved frigørelse af prostaglandin D2 (PGD2) i huden.
Nicotinic acid-induced flushing is mediated primarily by release of prostaglandin D2 (PGD2) in the skin.
Lægemiddel-/laboratorietest-interaktioner: I uringlucoseprøver kan nicotinsyre også give falsk positive reaktioner med opløsning af kobbersulfat (Benedicts prøve).
Medicinal product /laboratory test interactions: In urine glucose tests, nicotinic acid may also give false-positive reactions with cupric sulfate solution (Benedict's reagent).
Laropiprant har ingen effekt på lipidniveauerne og interfererer ikke med nicotinsyres indvirkning på lipider.
Laropiprant has no effect on lipid levels nor does it interfere with the effects of nicotinic acid on lipids.
Det er derfor ikke nødvendigt at tage aspirin for at mindske symptomerne på rødmen.
Therefore, taking aspirin to reduce flushing symptoms is not necessary.
• Hjertebanken (man mærker sit hjerteslag)
• palpitation (feeling your heartbeat)
Kapselformet, hvid/off-white tablet mærket med "552" på den ene side.
Capsule-shaped, white to off-white tablet, with “552” debossed on one side.
Efter 4 uger vil lægen måske hæve dosis til to tabletter om dagen.
After 4 weeks, your doctor may raise your dose of Pelzont to two tablets a day.
Hvis De har glemt at tage Pelzont
If you forget to take Pelzont
Nicotinsyre øger også HDL2-subfraktionen i højere grad end HDL3-subfraktionen og øger dermed HDL2:HDL3-ratioen, som er forbundet med nedsat kardiovalsulær risiko.
Nicotinic acid also elevates the HDL2 subfraction to a greater extent than the HDL3 subfraction, thereby increasing the HDL2:HDL3 ratio, which is associated with decreased cardiovascular disease risk.
Gennemsnitlig distributionsvolumen ved steady state efter en enkelt 40 mg intravenøs dosis af laropiprant til raske forsøgspersoner er ca. 70 liter.
The mean volume of distribution at steady state following a single 40 mg intravenous dose of laropiprant to healthy subjects is approximately 70 litres.
Behandling med acetylsalicylsyre til at mildne symptomerne på flushing er ikke nødvendig (se pkt.
Therefore, treatment with acetylsalicylic acid to alleviate flushing symptoms is not necessary (see section 5.1).
Andre forklaringer, som ikke udnævner plasma FFAreduktioner som central drivkraft for modificering af lipidprofilen, omfatter nicotinsyremedieret hæmning af de novo-lipogenese eller esterificering af fedtsyrer til TG i leveren.
Additional explanations that do not invoke plasma FFA reduction as the central driver of lipid profile modification include nicotinic acid-mediated inhibition of de novo lipogenesis or esterification of fatty acids into TG in the liver.
B. BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE UDLEVERING OG ANVENDELSE
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
• sænke det "dårlige" kolesterol.
• to lower your ‘bad' cholesterol level.
Nicotinsyre Ved overdosering af nicotinsyre bør understøttende forholdsregler anvendes.
Nicotinic acid For an overdose of nicotinic acid, supportive measures should be employed.
Laropiprant er ikke et substrat af humant P-gp, og derfor forventes andre hæmmere af CYP3A4 og/eller P-gp heller ikke at have en klinisk relevant indvirkning på laropiprants farmakokinetik.
Laropiprant is not a substrate of human P-gp, and therefore other inhibitors of CYP3A4 and/or P-gp are also not expected to have a clinically meaningful impact on the pharmacokinetics of laropiprant.
• Signifikant eller uforklarlig leverinsufficiens.
• Significant or unexplained hepatic dysfunction.
Farmakokinetisk steady state opnåedes inden for 2 dage efter dosering én gang dagligt af laropiprant med minimal akkumulation i AUC (ca. 1,3 gange) og Cmax (ca. 1,1 gange).
Pharmacokinetic steady state is achieved within 2 days of once-daily dosing of laropiprant, with minimal accumulation in AUC (approximately 1.3-fold) and Cmax (approximately 1.1-fold).
• Hurtig eller uregelmæssig hjerterytme (puls)
• rapid or irregular heartbeat
Det skal De vide, før De begynder at tage Pelzont
What you need to know before you take Pelzont
Pelzont er indiceret til behandling af dyslipidæmi, især hos voksne patienter med kombineret dyslipidæmi (karakteriseret ved forhøjede koncentrationer af LDL-kolesterol og triglycerider samt lavt HDL-kolesterol) og hos voksne patienter med primær hyperkolesterolæmi (heterozygot familiær og non-familiær).
Pelzont is indicated for the treatment of dyslipidaemia, particularly in adult patients with combined mixed dyslipidaemia (characterised by elevated levels of LDL-cholesterol and triglycerides and low HDL-cholesterol) and in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial).
Pædiatrisk population Pelzont: Der er ikke udført undersøgelser med børn.
Paediatric population Pelzont: No studies have been performed in paediatric patients.
Kosttilskud med nicotinsyre: Vitaminer eller andre ernæringstilskud med (≥ 50 mg /dag) nicotinsyre (eller nicotinamid) er ikke blevet undersøgt sammen med Pelzont.
Supplements containing nicotinic acid: Vitamins or other nutritional supplements containing (≥ 50 mg/day) of nicotinic acid (or nicotinamide) have not been studied with Pelzont.
Patienter med lever- eller nyreinsufficiens
Patients with hepatic or renal insufficiency
Skift fra nicotinsyre med umiddelbar udløsning (krystallinsk) til Pelzont er ikke undersøgt.
Switching from immediate-release (crystalline) nicotinic acid to Pelzont has not been studied.
I disse undersøgelser var procentdelen af patienter, der fik Pelzont, nicotinsyre (depotformuleringer, poolede) eller placebo/simvastatin (poolet), og som stoppede behandlingen på grund af flushing-relaterede symptomer (rødme, varme, kløe og prikken i huden) henholdsvis 7,2 %, 16,6 % og 0,4 %.
In these studies, the percentage of patients taking Pelzont, nicotinic acid (pooled prolonged-release formulations) or pooled placebo/simvastatin who discontinued due to any flushing-related symptom (redness, warmth, itching and tingling) was 7.2 %, 16.6 %, and 0.4 %, respectively.
• Muskulær toksicitet i anamnesen med statin eller fibrat.
• Previous history of muscular toxicity with a statin or fibrate
*Inkluderer patienter med moderate, svære eller ekstreme flushing-symptomer
*Includes patients with moderate, severe, or extreme flushing symptoms †Dose advancement at Week 5
MÆRKNING, DER SKAL ANFØRES PÅ DEN MELLEMSTE EMBALLAGE Multipakninger à 196 (2 pakninger à 98 tabletter med modificeret udløsning) - uden blå boks (til PVC/Aclar blister)
PARTICULARS TO APPEAR ON THE INTERMEDIATE CARTON Multi-packs of 196 (2 packs of 98 modified-release tablets) - without blue box (for PVC/Aclar blister)
På samme måde som LDL kan også kolesterol- og triglyceridholdige lipoproteiner, inklusive VLDL, intermediate-density lipoproteins (IDL) og rester, fremme aterosklerose.
Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis.
1'hydroxymidazolam metaboliseres overvejende af uridindiphosphat glucuronosyltransferaserne (UGT) 2B4 og 2B7.
1'-hydroxymidazolam is metabolised predominantly by uridine diphosphate-glucuronosyltransferases (UGT) 2B4 and 2B7.
I tre store kliniske undersøgelser, hvor patientrapporterede flushing-symptomer blev målt, oplevede de patienter, der tog Pelzont, mindre flushing end de patienter, der tog nicotinsyre (depotformuleringer).
In three large clinical trials measuring patient-reported flushing symptoms, patients taking Pelzont experienced less flushing than those taking nicotinic acid (prolonged-release formulations).
I den anden undersøgelse (16 uger), hvor acetylsalicylsyre var tilladt, oplevede de patienter, der fik Pelzont, signifikant færre dage pr. uge med moderat eller mere udbredt flushing sammenlignet med nicotinsyre (taget som depotformulering med multi-step titrering fra 500 mg til 2.000 mg over 12 uger) (p < 0,001).
In the second study (16 weeks) where acetylsalicylic acid was allowed, patients taking Pelzont experienced significantly fewer days per week with moderate or greater flushing compared to nicotinic acid (prolonged-release formulation taken as a 12-week multi-step 500 mg to 2,000 mg titration) (p< 0.001).
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE YDRE KARTON (til PVC/Aclar blister)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (for PVC/Aclar blister)
Kolesterol er et af flere fedtstoffer i blodet.
Cholesterol is one of several fats found in your blood.
Nicotinsyre sænker koncentrationen af low-density lipoprotein kolesterol (LDL-C), totalt kolesterol (TC), very low density lipoprotein kolesterol (VLDL-C), apolipoprotein-B (apo-B, det væsentlige LDL-protein) triglycerider (TG) og lipoprotein(a) (Lp(a), en modificeret LDL-partikel) og øger koncentrationen af high-density lipoprotein kolesterol (HDL-C) og apolipoprotein-A-I (apo-A-I, den væsentlige proteinkomponent i HDL).
Nicotinic acid lowers the levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), very low density lipoprotein cholesterol (VLDL-C), apolipoprotein B (apo B, the major LDL protein), triglycerides (TG), and lipoprotein(a) (Lp(a), a modified LDL particle) and elevates the levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I (apo A-I, the major protein component of HDL).
Nicotinsyre: Farmakokinetiske data for ældre (≥ 65 år) er ikke tilgængelige.
Nicotinic acid: There is no pharmacokinetic data in the elderly (≥ 65 years).
Toksikologiske fund i disse undersøgelser af samtidig administration var i overensstemmelse med de fund, der blev gjort, når nicotinsyre og laropiprant blev administreret enkeltvis.
Toxicologic findings in these co-administration studies were consistent with those seen with nicotinic acid and laropiprant administered individually.
Der er ikke udført undersøgelser med Pelzont hos diegivende dyr.
No studies in lactating animals have been conducted with Pelzont.
Der er hyppigt fundet forhøjede TG-koncentrationer i plasma i en triade med lave HDL-C-koncentrationer og små LDLpartikler og også i forbindelse med non-lipide metaboliske risikofaktorer for koronar hjertesygdom.
Elevated plasma TG levels are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease (CHD).
Sjældne tilfælde af myopati/rhabdomyolyse er blevet forbundet med samtidig administration af lipidsænkende doser (≥ 1.000 mg/dag) af nicotinsyre og HMG-CoA-reduktasehæmmere (statiner) (se pkt.
Rare cases of myopathy/rhabdomyolysis have been associated with concomitant administration of lipid-altering doses (≥ 1,000 mg/day) of nicotinic acid and HMG-CoA reductase inhibitors (statins) (see section 4.8).
I kontrollerede kliniske undersøgelser var incidensen af klinisk relevante stigninger i serumtransaminaser (ALAT og/eller ASAT ≥ 3 x ULN (øvre normalgrænse) konsekutivt) 1,0 % for patienter, der blev behandlet med Pelzont med eller uden et statin.
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/or AST ≥ 3 X ULN, consecutive) was 1.0 % for patients treated with Pelzont with or without a statin.
kolesterol, fedtholdige stoffer (triglycerider) og apo-B (en del af LDL) i blodet.
LDL cholesterol, fatty substances called triglycerides and apo B (a part of LDL) in the blood;
Den hepatocellulære centrilobulære hypertrofi var i overensstemmelse med den specifikke enzyminduktion hos gnavere.
The hepatocellular centrilobular hypertrophy was consistent with rodent specific enzyme induction.
Dette sker ved at sænke den totale mængde af kolesterol, LDL
It does this by lowering the levels of total cholesterol,
Fertilitet Data fra dyreforsøg er utilstrækkelige med hensyn til indvirkning på fertiliteten (se pkt.
Fertility Animal studies are insufficient with respect to impairment on fertility (see section 5.3).
HMG-CoA reduktasehæmmere: Når simvastatin kombineredes med nicotinsyre, sås en beskeden stigning i simvastatinsyres (den aktive form af simvastatin) AUC og Cmax, som kan være uden klinisk relevans.
HMG-CoA reductase inhibitors: When simvastatin is combined with nicotinic acid, a modest increase in AUC and Cmax of simvastatin acid (the active form of simvastatin) was observed, which may be devoid of clinical relevance.
Nicotinsyre
Nicotinic acid
Der er ingen forskel i nicotinsyres perorale biotilgængelighed hos mænd og kvinder, der får Pelzont.
There is no difference in the oral bioavailability of nicotinic acid in men and women receiving Pelzont.
Almindelig: stigninger i ALAT og/eller ASAT (konsekutivt, ≥ 3 X ULN), fasteglucose (se nedenfor) Ikke almindelig: stigninger i kreatinkinase (≥ 10 X ULN), LDH,
Common: elevations in ALT and/or AST (consecutive, ≥ 3 X ULN), fasting glucose (see below) Uncommon: elevations in CK (≥ 10 X ULN), LDH, uric acid (see
Øjne: Cystisk makulært ødem, toksisk amblyopi.
Eye disorders: Cystoid macular oedema, toxic amblyopia.
• De tidligere har haft leversygdom, gulsot (leversygdom, der medfører gulfarvning af huden og det hvide i øjnene) eller sygdom i lever og galdegang (hepatobiliær sygdom).
• you have ever had liver disease, jaundice (a liver disorder causing yellowing of the skin and whites of the eyes), or hepatobiliary (liver and bile duct) disease.
Lægen bør overveje indtaget af nicotinsyre fra vitaminer og enæringstilskud, når Pelzont ordineres.
Physicians should consider the nicotinic acid intake from vitamins and nutritional supplements when prescribing Pelzont.
Nicotinsyre hæmmer frigørelsen af frie fedtsyrer (FFA) fra adipøst væv, som kan bidrage til reduceret plasma LDL-C, TC, VLDL-C, apo-B, TG og Lp(a) samt forhøjet HDL-C og apo-A-I, som alle er forbundet med lavere kardiovaskulær risiko.
Nicotinic acid inhibits release of free fatty acids (FFA) from adipose tissue, which may contribute to the reduced plasma LDL-C, TC, VLDL-C, apo B, TG, and Lp(a), as well as elevated HDL-C, and apo A-I, all of which are associated with lower cardiovascular risk.
Laropiprant hæmmer PGD2-medieret flushing, som er forbundet med administration af nicotinsyre.
Laropiprant suppresses PGD2 mediated flushing associated with administration of nicotinic acid.
Pelzont kan anvendes som monoterapi hos patienter, hvor HMG-CoA-reduktasehæmmere anses for at være uhensigtsmæssige eller ikke tåles.
It can be used as monotherapy only in patients in whom HMG-CoA reductase inhibitors are considered inappropriate or not tolerated.
Pelzont indeholder et sukkerstof, der kaldes lactose.
Pelzont contains a sugar called lactose.
Gå til lægen regelmæssigt for at følge Deres kolesteroltal, og tal med lægen om målet for Dem.
Your doctor can measure your cholesterol with a simple blood test. Visit your doctor regularly to keep track of your cholesterol and discuss your goals with your doctor.
Fortæl det også til lægen, hvis De er kineser og tager simvastatin (et statin) eller medicin, der indeholder simvastatin.
Also tell your doctor if you are taking simvastatin (a statin) or a medicine containing simvastatin and are Chinese.
Hypromellose (E464) Silica, kolloid vandfri (E551) Natriumstearylfumarat Hydroxypropylcellulose (E463) Mikrokrystallinsk cellulose (E460) Croscarmellosenatrium Lactosemonohydrat Magnesiumstearat
Hypromellose (E464) Colloidal anhydrous silica (E551) Sodium stearyl fumarate Hydroxypropylcellulose (E463) Microcrystalline cellulose (E460) Croscarmellose sodium Lactose monohydrate Magnesium stearate